Author Correction: β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Author Correction: β-catenin drives resistance to PI3K and AKT inhibitors and promotes colon cancer metastasis by disrupting FOXO3a function

  • By

  • Stephan P. Tenbaum

  • Paloma Ordóñez-Morán

  • Isabel Puig

  • Irene Chicote

  • Oriol Arqués

  • Stefania Landolfi

  • Yolanda Fernández

  • José Raúl Herance

  • Juan D. Gispert

  • Leire Mendizabal

  • Susana Aguilar

  • Santiago Ramón y. Cajal

  • Simó Schwartz

  • Ana Vivancos

  • Eloy Espín

  • Santiago Rojas

  • José Baselga

  • Josep Tabernero

  • Alberto Muñoz

  • Héctor G. Palmer

  • October 22, 2026

Share

Clinical Report: Correction to β-catenin and colon cancer metastasis report

Overview

A correction to the 2012 Nature Medicine report identifies a duplicated image in Fig. 6b under “T49, Xenograft.” The corrected panel replaces it with a different representative confocal image corresponding to the staining described in the article; the notice amends this specific error in the original publication.

Background

The original report, DOI 10.1038/nm.2772, was published online on 20 May 2012 and concerned β-catenin, resistance to PI3K and AKT inhibitors, and colon cancer metastasis. The correction addresses the accuracy of a figure panel rather than reporting new experimental findings. The supplied context does not provide additional methods, numerical results, or clinical outcomes from the original study.

Data Highlights

ItemCorrection detail
Original reportNature Medicine; DOI 10.1038/nm.2772; published online 20 May 2012
Location of errorFig. 6b, “T49, Xenograft”
Identified issueThe panel contained an image duplicated from Fig. 1b
CorrectionThe corrected panel contains a different representative confocal image corresponding to the staining described

Key Findings

  • The correction concerns Fig. 6b of the report on β-catenin and colon cancer metastasis.
  • The “T49, Xenograft” image in the initially published Fig. 6b was duplicated from Fig. 1b.
  • The corrected Fig. 6b replaces that image with a different representative confocal image.
  • The notice states that the replacement image corresponds to the staining described in the article.
  • The correction amends the identified figure error; the supplied notice does not report other changes or new findings.

Clinical Implications

This notice documents a correction to a representative image and does not provide new clinical outcome data or treatment guidance. The supplied material does not establish implications for patient management.

Conclusion

The correction replaces the duplicated “T49, Xenograft” image in Fig. 6b with the intended representative confocal image. Its stated scope is limited to this figure-panel amendment.

Related Resources & Content

  1. Nature Medicine, 2012 — Author Correction: β-catenin drives resistance to PI3K and AKT inhibitors and promotes colon cancer metastasis by disrupting FOXO3a function
  2. ASCO Publications — Manipulation of β-catenin pathway to overcome endocrine resistance in breast cancer.
  3. Nature Cancer — Correction: Scribble mis-localization drives adaptive resistance to KRAS G12C inhibitors via YAP-induced MRAS and feedback activation of MAPK signaling
  4. ASCO Publications — FKBP10-inhibited β-catenin ubiquitination in the malignant transformation of breast epithelial cells.
  5. ASCO Publications — FKBP10-inhibited β-catenin ubiquitination in the malignant transformation of breast epithelial cells.
  6. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up - PubMed
  7. From PIK3CA Mutations to Rational PI3K Inhibition for the Treatment of Colorectal Cancer

Original Source(s)

Related Content